T2 Biosystems Inc
NASDAQ:TTOO
Intrinsic Value
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. [ Read More ]
The intrinsic value of one
TTOO
stock under the Base Case scenario is
87.9
USD.
Compared to the current market price of 2.63 USD,
T2 Biosystems Inc
is
Undervalued by 97%.
T2 Biosystems Inc's market capitalization is 13m USD.
TTOO stock price is 2.63 USD.
TTOO stock price (2.63 USD) is 97% less than its Intrinsic Value (87.9 USD).
TTOO. Open DCF Valuation
TTOO has upside potential of 365% compared to the average analyst price target.
Open Wall St Estimates
TTOO has positive Net Debt. This means that the company has more debt (41m USD) than cash and short-term investments (16m USD).
TTOO's Revenue has dropped by 68% over the past 12 months.
TTOO's ROE (Return on Equity) has significantly decreased in the last 3 years from 1 028% to 148%.
TTOO's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -162% to -234%, and is approaching profitability.
TTOO has negative Operating Income for the last twelve months.
TTOO has negative Net Income for the last twelve months.
TTOO's ROE (Return on Equity) for the past 12 months is very high and is equal to 148%.
TTOO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -234%.
TTOO's long-term liabilties (63m USD) exceed its long-term assets (35m USD).
TTOO has negative Gross Profit for the last twelve months.
TTOO's Revenue is forecast to grow at a rate of 94% per year over the next 3 years.
TTOO's short-term liabilties (56m USD) exceed its short-term assets (25m USD).
TTOO's Revenue has been falling by 27% per year for the last 3 years.
TTOO has negative Free Cash Flow for the last twelve months.
TTOO has very high three-year average ROE (Return on Equity): 257%. The company is very efficient at transforming stockholders' equity into net income.
TTOO has negative three-year average ROIC (Return on Invested Capital): -204%. The company is not efficient at using invested capital to generate operating income.
TTOO's D/E (Debt to Equity) is very low and is equal to -1.47.
TTOO's Altman Z-Score is very low and is equal to -27.66.
TTOO doesn't generate enough operating income (-47m USD) to safely cover interest payments on its debt (4m USD).
Fundamental Analysis
T2 Biosystems Inc
Balance Sheet Decomposition
T2 Biosystems Inc
| Current Assets | 25.2m |
| Cash & Short-Term Investments | 15.7m |
| Receivables | 1.4m |
| Other Current Assets | 8.1m |
| Non-Current Assets | 9.6m |
| PP&E | 9.1m |
| Other Non-Current Assets | 555k |
| Current Liabilities | 56.2m |
| Accounts Payable | 1.5m |
| Accrued Liabilities | 11.3m |
| Short-Term Debt | 41.3m |
| Other Current Liabilities | 2m |
| Non-Current Liabilities | 6.7m |
| Other Non-Current Liabilities | 6.7m |
Earnings Waterfall
T2 Biosystems Inc
|
Revenue
|
7.2m
USD
|
|
Cost of Revenue
|
-15.4m
USD
|
|
Gross Profit
|
-8.2m
USD
|
|
Operating Expenses
|
-39m
USD
|
|
Operating Income
|
-47.2m
USD
|
|
Other Expenses
|
-2.9m
USD
|
|
Net Income
|
-50.1m
USD
|
Free Cash Flow Analysis
T2 Biosystems Inc
TTOO Profitability Score
Profitability Due Diligence
T2 Biosystems Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
T2 Biosystems Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
TTOO Solvency Score
Solvency Due Diligence
T2 Biosystems Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.
Score
T2 Biosystems Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TTOO Price Targets Summary
T2 Biosystems Inc
According to Wall Street analysts, the average 1-year price target for
TTOO
is 12.24 USD
with a low forecast of 12.12 USD and a high forecast of 12.6 USD.
Ownership
TTOO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
TTOO Price
T2 Biosystems Inc
| Average Annual Return | -48.17% |
| Standard Deviation of Annual Returns | 45.53% |
| Max Drawdown | -100% |
| Market Capitalization | 13m USD |
| Shares Outstanding | 4 930 000 |
| Percentage of Shares Shorted | 8.47% |
Company Profile
T2 Biosystems Inc
Country
Industry
Market Cap
Dividend Yield
Description
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 182 full-time employees. The company went IPO on 2014-08-07. The firm is focused on rapid detection of sepsis-causing pathogens and antibiotic resistance genes. The firm is using its T2MR technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its products include the T2Dx Instrument, T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel that are all powered by the T2MR technology. Its T2Candida Panel is a direct-from-blood test that identifies the lethal form of common blood stream infections that cause sepsis and candidemia. Its T2Bacteria Panel is a direct-from-blood test that detects certain bacterial pathogens associated with sepsis.
You don't have any saved screeners yet
